Amrize AG gains as Oakmark fund initiates position
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2025
0mins
Should l Buy AMRZ?
Source: SeekingAlpha
Amrize AG's stock rose by 4.51% and reached a 52-week high during regular trading.
The Oakmark U.S. Large Value Strategy has initiated a position in Amrize AG, reflecting optimism about the building materials and construction solutions sector. This strategic move comes amid a strong performance in the broader market, with the Nasdaq-100 up 1.89% and the S&P 500 up 1.78%.
This positive sentiment from a reputable investment fund may enhance investor confidence in Amrize AG, potentially leading to further gains in the stock price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMRZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMRZ
Wall Street analysts forecast AMRZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRZ is 59.94 USD with a low forecast of 52.44 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
10 Buy
5 Hold
0 Sell
Moderate Buy
Current: 55.600
Low
52.44
Averages
59.94
High
70.00
Current: 55.600
Low
52.44
Averages
59.94
High
70.00
About AMRZ
Amrize Ltd delivers advanced building solutions from foundation to rooftop. The Company serves customers across infrastructure, commercial and residential markets and from new build to repair and refurbishment in North America. With over 1,000 sites and a distribution network, it delivers for customers in every U.S. state and Canadian province. Its two businesses, Building Materials and Building Envelope, offer advanced branded solutions to cover construction needs from foundation to rooftop. Its Building Materials business includes cement, concrete, aggregates, and asphalt. Its cement brands include OneCem, ECOPlanet Cements, and MaxCem. Its concrete brands include ECOPact, DYNAMax, and Ductal. Its Building Envelope business includes commercial roofing, residential roofing, weatherization, adhesives and sealants, and insulation. Its commercial roofing brands are Elevate, Duro-Last, GenFlex, and Gaco. Its insulation brands include Enverge, OX Engineered Products, and others.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Return on Investment: The Oakmark U.S. Large Value Strategy achieved a net return of 4.79% in Q4, significantly outperforming the Russell 1000 Value Index's 3.81%, indicating the effectiveness of its investment strategy and market adaptability.
- New Portfolio Positions: During this period, the fund initiated positions in AerCap Holdings, the world's largest aircraft lessor, Amrize, a producer of building materials and construction solutions, and CDW Corporation, an IT solutions company, reflecting optimism about these sectors' prospects.
- Position Reduction Strategy: Concurrently, the fund eliminated its holdings in Bank of New York Mellon and Magna, indicating a cautious outlook on these companies' future performance amid changing market conditions.
- Market Outlook Analysis: Despite macroeconomic challenges, Bank of New York Mellon's Q4 earnings report demonstrated strong business performance; however, its shares are still considered pricey, suggesting that investors should carefully assess its investment value.
See More

- Performance Overview: The Oakmark Fund (Investor Class) achieved a 4.78% return in Q4 2025, significantly outperforming the S&P 500 Index's 2.66%, demonstrating the effectiveness of its investment strategy and market adaptability.
- New Investment Positions: In Q4 2025, the fund added new positions in AerCap (NYSE:AER), Amrize (NYSE:AMRZ), and CDW (NASDAQ:CDW), indicating a positive outlook on the aviation leasing and technology services sectors, aiming to enhance overall returns through diversified investments.
- Exit Strategy Adjustments: The fund exited its positions in Bank of New York Mellon (BK) and Magna (MGA) during Q4 2025, reflecting its keen insight into market dynamics and the ability to flexibly adjust its portfolio to optimize risk-return profiles.
- Market Commentary Insights: The Oakmark Fund's Q4 2025 commentary reveals a profound understanding of the U.S. equity market, providing valuable insights for investors by combining market trends with portfolio performance, thereby enhancing trust among its investor base.
See More
- Strong Quarterly Performance: The Oakmark Equity and Income Fund outperformed both the S&P 500 and Bloomberg U.S. Aggregate Bond Index in Q4, demonstrating the effectiveness of its investment strategy and market adaptability.
- Sector Contribution Analysis: Communication services and healthcare were the largest contributors to performance, while industrials detracted, reflecting a market preference for value and smaller capitalization stocks.
- New Investment Positions: The fund initiated new positions in Amrize (AMRZ), Gartner (IT), and Mondelez International (MDLZ), indicating a positive outlook on their future growth potential.
- Exit Strategy: The fund exited positions in BlackRock (BLK) and Charter Communications (CHTR), showcasing its responsiveness to market dynamics and proactive portfolio management.
See More
- Sales Forecast Downgrade: Travere Therapeutics expects U.S. net product sales of $410 million for 2025 and $127 million for Q4 2026, indicating pressure on future revenue growth that could undermine investor confidence.
- Clinical Trial Restart: The company plans to restart the Phase 3 HARMONY study in Q1 2026, aiming to advance product development, but this may not alleviate the short-term stock price decline.
- Severe Market Reaction: Shares of Travere Therapeutics plummeted 28.2% to $24.50 in pre-market trading, reflecting a pessimistic outlook from the market that may lead investors to reassess their strategies.
- Other Stock Volatility: Lulu’s Fashion Lounge Holdings surged 79% on acquisition news but fell 10.4% in pre-market trading, highlighting the high volatility in market sentiment that could impact the overall investment landscape.
See More

- Market Opening: U.S. stock markets are set to open in two hours.
- L3Harris Technologies Inc. Performance: L3Harris Technologies Inc. (LHX) saw a 13.0% increase in pre-market trading.
- Revvity Inc. Performance: Revvity Inc. (RVTY) experienced a 6.9% rise in pre-market trading.
- Overall Market Sentiment: The pre-market gains indicate positive sentiment for these companies ahead of the market opening.
See More
- Significant Stock Surge: Heritage Global Inc's shares rose 19.1% to $1.62 in pre-market trading, reflecting strong market confidence in the company's growth potential following the acquisition announcement.
- Acquisition Details: The company's subsidiary, Heritage DebtX, acquired substantially all assets of The Debt Exchange, which not only strengthens its asset base but also enhances its competitive position in the debt trading market.
- Strong Market Reaction: The acquisition news generated significant investor interest, with Heritage Global's stock performing notably well in pre-market trading, indicating market approval of its strategic direction.
- Future Growth Potential: This acquisition positions Heritage Global to capture a larger market share in debt management and trading, potentially leading to long-term revenue growth and business expansion opportunities.
See More








